Lead Product(s): CDNF
Therapeutic Area: Neurology
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2020
Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson's disease patients, with encouraging biological responses.